首页 | 本学科首页   官方微博 | 高级检索  
     


Binding and Cytotoxicity of HPMA Copolymer Conjugates to Lymphocytes Mediated by Receptor-Binding Epitopes
Authors:Tang  Aijun  Kopečková   Pavla  Kopeček  Jindřich
Affiliation:(1) Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, 84112;(2) Department of Bioengineering, University of Utah, Salt Lake City, Utah, 84112
Abstract:Purpose. Studies on the recognition of epitopes presented on a template peptide showed the potential of nonapeptide-related sequences to act as biorecognition sites for the B-cell CD21 receptor. This study was intended to evaluate the capability of three epitope sequences to mediate specific cell binding and to enhance the cytotoxicity of HPMA copolymer conjugates.Methods. HPMA copolymer conjugates were synthesized containing three different epitopes at various contents and either a fluorescent marker or doxorubicin (DOX). The binding and cytotoxicity of the conjugates to CD21+ Raji B cells and CD21 HSB-2 T cells were evaluated.Results. The epitope-containing conjugates were found to bind to Raji cells at different apparent affinities depending on epitope structure and content. The conjugates generally possessed higher affinities for Raji cells than for HSB-2 cells. Targeted HPMA copolymer-DOX conjugates exhibited higher cytotoxicities than the nontargeted conjugate, likely indicative of enhanced internalization by receptor-mediated endocytosis. HSB-2 cells were more sensitive to both free and polymer-bound DOX than Raji cells; however, the enhancement of cytotoxicity of the conjugates by incorporation of epitopes was more pronounced for Raji cells.Conclusions. The results verified the concept of using receptor-binding epitopes as targeting moieties in HPMA copolymer conjugates for the delivery of anticancer drugs to lymphoma cells.
Keywords:HPMA copolymer conjugates  epitope  CD21 receptor  binding affinity  cytotoxicity  lymphocytes
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号